Text Size

Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Hadassah Medical Organization.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00159003
First received: September 8, 2005
Last updated: June 22, 2011
Last verified: June 2011
History of Changes
  Purpose

There are naturally occuring variations in the genetic makeup of all of us. Some of these variations may contribute to a change in susceptibility toward different diseases or change the prognosis.

We are studying these genetic variations in patients with leukemia. The genes we are studying are those which influence detoxification of drugs and toxins.


Condition
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Molecular Analysis of Genetic Elements Which May Influence Predisposition and Prognosis of Hematological Malignancies in Different Ethnic Groups in Israel

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Biospecimen Retention:   Samples With DNA

DNA only


Estimated Enrollment: 300
Study Start Date: January 1998
Estimated Study Completion Date: April 2012
Detailed Description:

We have prepared DNA on patients with leukemia (AML, CML and CLL) and we are studying the influence of polymorphisms in drug metabolism and disposition genes on predisposition and prognosis of these types of leukemia. The genes we are studying include: MDR1, CYP3A4, NQO1, NAT1/2, GST, hOCT. We plan to study other genes that may be contributory.

Study includes comparing the frequency of polymorphisms in these genes with the frequency in the general population and the study of DNA biding proteins which bind at the sites of these polymorphisms.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients admitted to Hadassah Hospital with AML or CLL.

Criteria

Inclusion Criteria:

  • diagnosis of acute myeloid leukemia or chronic lymphocytic leukemia

Exclusion Criteria:

  • under 18 years of age
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00159003

Contacts
Contact: Deborah G Rund, MD 972-2-6778712 rund@cc.huji.ac.il

Locations
Israel
Hadassah Medical Organization Recruiting
Jerusalem, Israel, IL91120
Contact: Deborah G Rund, MD     972-2-6778712     rund@cc.huji.ac.il    
Principal Investigator: Deborah G Rund, MD            
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Deborah G Rund, MD Hadassah Medical Organization
  More Information

Publications:

Responsible Party: Deborah Rund, Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00159003     History of Changes
Other Study ID Numbers: 132910-HMO-CTIL
Study First Received: September 8, 2005
Last Updated: June 22, 2011
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
drug metabolism and disposition enzymes

Additional relevant MeSH terms:
Disease Susceptibility
Genetic Predisposition to Disease
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hematologic Neoplasms
Disease Attributes
Pathologic Processes
 Neoplasms by Histologic Type
Neoplasms
Leukemia, B-Cell
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Neoplasms by Site

ClinicalTrials.gov processed this record on June 17, 2013